Alternative splicing of human NT5E in cirrhosis and hepatocellular carcinoma produces a negative regulator of ecto-52-nucleotidase (CD73)

Molecular Biology of the Cell

Volumn 25, Issue 25, 2014, Pages 4024-4033

  Snider, Natasha T ^a   Altshuler, Peter J ^a   Wan, Shanshan ^a   Welling, Theodore H ^a   Cavalcoli, James ^a   Omarya, M Bishr ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALNEXIN; CD73S PROTEIN; ECTO 5' NUCLEOTIDASE; KI 67 ANTIGEN; MESSENGER RNA; NUCLEOTIDASE; UNCLASSIFIED DRUG; 5' NUCLEOTIDASE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; NT5E PROTEIN, HUMAN; PROTEASOME;

ALTERNATIVE RNA SPLICING; ARTICLE; CATALYSIS; CHICKEN; CHIMPANZEE; COMPLEX FORMATION; CONTROLLED STUDY; COW; DATA BASE; DIMERIZATION; DOG; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; ENZYME DEGRADATION; GENE; GENE CONTROL; GENE EXPRESSION; GENETIC IDENTIFICATION; GENETIC VARIABILITY; GENOMICS; GLYCOSYLATION; HEPG2 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MOUSE; NONHUMAN; NT5E GENE; OPOSSUM; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SEQUENCE ALIGNMENT; SPECIES COMPARISON; UPREGULATION; XENOPUS; ZEBRA FISH; AMINO ACID SEQUENCE; ANIMAL; ENZYMOLOGY; GENETICS; LIVER TUMOR; METABOLISM; MOLECULAR GENETICS; PROTEIN MULTIMERIZATION; SPECIES DIFFERENCE; TUMOR CELL LINE;

5'-NUCLEOTIDASE; ALTERNATIVE SPLICING; AMINO ACID SEQUENCE; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; GENE EXPRESSION; GPI-LINKED PROTEINS; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MICE; MOLECULAR SEQUENCE DATA; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN MULTIMERIZATION; SPECIES SPECIFICITY;

EID: 84919492939     PISSN: 10591524     EISSN: 19394586     Source Type: Journal    
DOI: 10.1091/mbc.E14-06-1167     Document Type: Article

References (50)

1. Algars A, Karikoski M, Yegutkin GG, Stoitzner P, Niemela J, Salmi M, Jalkanen S (2011). Different role of CD73 in leukocyte trafficking via blood and lymph vessels. Blood 117, 4387-4393.
2. Allard B, Turcotte M, Spring K, Pommey S, Royal I, Stagg J (2014). Anti-CD73 therapy impairs tumor angiogenesis. Int J Cancer 134, 1466-1473.
3. Antonioli L, Blandizzi C, Pacher P, Hasko G (2013a). Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer 13, 842-857.
4. Antonioli L, Pacher P, Vizi ES, Hasko G (2013b). CD39 and CD73 in immunity and inflammation. Trends Mol Med 19, 355-367.
5. Barbosa-Morais NL, Irimia M, Pan Q, Xiong HY, Gueroussov S, Lee LJ, Slobodeniuc V, Kutter C, Watt S, Colak R, et al. (2012). The evolutionary landscape of alternative splicing in vertebrate species. Science 338, 1587-1593.
6. Beavis PA, Stagg J, Darcy PK, Smyth MJ (2012). CD73: a potent suppressor of antitumor immune responses. Trends Immunol 33, 231-237.
7. Brownell J, Polyak SJ (2013). Molecular pathways: hepatitis C virus, CXCL10, and the inflammatory road to liver cancer. Clin Cancer Res 19, 1347-1352.
8. Chan TH, Lin CH, Qi L, Fei J, Li Y, Yong KJ, Liu M, Song Y, Chow RK, Ng VH, et al. (2014). A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma. Gut 63, 832-843.
9. Chen JF, Eltzschig HK, Fredholm BB (2013). Adenosine receptors as drug targets-what are the challenges? Nat Rev Drug Discov 12, 265-286.
10. Chen R, Jiang X, Sun D, Han G, Wang F, Ye M, Wang L, Zou H (2009). Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry. J Proteome Res 8, 651-661.
11. Chettouh H, Fartoux L, Aoudjehane L, Wendum D, Claperon A, Chretien Y, Rey C, Scatton O, Soubrane O, Conti F, et al. (2013). Mitogenic insulin receptor-A is overexpressed in human hepatocellular carcinoma due to EGFR-mediated dysregulation of RNA splicing factors. Cancer Res 73, 3974-3986.
12. Cohen S, Stemmer SM, Zozulya G, Ochaion A, Patoka R, Barer F, Bar-Yehuda S, Rath-Wolfson L, Jacobson KA, Fishman P (2011). CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver. J Cell Physiol 226, 2438-2447.
13. Colgan SP, Eltzschig HK, Eckle T, Thompson LF (2006). Physiological roles for ecto-5'-nucleotidase (CD73). Purinergic Signal 2, 351-360.
14. David CJ, Manley JL (2010). Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev 24, 2343-2364.
15. De Craene B, Berx G (2013). Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 13, 97-110.
16. Fausther M, Lavoie EG, Goree JR, Baldini G, Dranoff JA (2014). NT5E mutations that cause human disease are associated with intracellular mistrafficking of NT5E protein. PLoS One 9, e98568.
17. Fausther M, Sheung N, Saiman Y, Bansal MB, Dranoff JA (2012). Activated hepatic stellate cells upregulate transcription of ecto-5'-nucleotidase/CD73 via specific SP1 and SMAD promoter elements. Am J Physiol Gastrointest Liver Physiol 303, G904-G914.
18. Flicek P, Amode MR, Barrell D, Beal K, Billis K, Brent S, Carvalho-Silva D, Clapham P, Coates G, Fitzgerald S, et al. (2014). Ensembl 2014. Nucleic Acids Res 42, D749-D755.
19. Harte RA, Farrell CM, Loveland JE, Suner MM, Wilming L, Aken B, Barrell D, Frankish A, Wallin C, Searle S, et al. (2012). Tracking and coordinating an international curation effort for the CCDS Project. Database (Oxford) 2012, bas008.
20. Hermes M, Osswald H, Kloor D (2007). Role of S-adenosylhomocysteine hydrolase in adenosine-induced apoptosis in HepG2 cells. Exp Cell Res 313, 264-283.
21. Knapp K, Zebisch M, Pippel J, El-Tayeb A, Muller CE, Strater N (2012). Crystal structure of the human ecto-5'-nucleotidase (CD73): insights into the regulation of purinergic signaling. Structure 20, 2161-2173.
22. Lee TK, Murthy SR, Cawley NX, Dhanvantari S, Hewitt SM, Lou H, Lau T, Ma S, Huynh T, Wesley RA, et al. (2011). An N-terminal truncated carboxy?peptidase E splice isoform induces tumor growth and is a biomarker for predicting future metastasis in human cancers. J Clin Invest 121, 880-892.
23. Loi S, Pommey S, Haibe-Kains B, Beavis PA, Darcy PK, Smyth MJ, Stagg J (2013). CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci USA 110, 11091-11096.
24. Luco RF, Allo M, Schor IE, Kornblihtt AR, Misteli T (2011). Epigenetics in alternative pre-mRNA splicing. Cell 144, 16-26.
25. Matera AG, Wang Z (2014). A day in the life of the spliceosome. Nat Rev Mol Cell Biol 15, 108-121.
26. Merkin J, Russell C, Chen P, Burge CB (2012). Evolutionary dynamics of gene and isoform regulation in mammalian tissues. Science 338, 1593-1599.
27. Mikhailov A, Sokolovskaya A, Yegutkin GG, Amdahl H, West A, Yagita H, Lahesmaa R, Thompson LF, Jalkanen S, Blokhin D, et al. (2008). CD73 participates in cellular multiresistance program and protects against TRAIL-induced apoptosis. J Immunol 181, 464-475.
28. Misumi Y, Ogata S, Ohkubo K, Hirose S, Ikehara Y (1990). Primary structure of human placental 5'-nucleotidase and identification of the glycolipid anchor in the mature form. Eur J Biochem/FEBS 191, 563-569.
29. Peng Z, Borea PA, Varani K, Wilder T, Yee H, Chiriboga L, Blackburn MR, Azzena G, Resta G, Cronstein BN (2009). Adenosine signaling contributes to ethanol-induced fatty liver in mice. J Clin Invest 119, 582-594.
30. Peng Z, Fernandez P, Wilder T, Yee H, Chiriboga L, Chan ES, Cronstein BN (2008). Ecto-5'-nucleotidase (CD73)-mediated extracellular adenosine production plays a critical role in hepatic fibrosis. FASEB J 22, 2263-2272.
31. Qi L, Chan TH, Tenen DG, Chen L (2014). RNA editome imbalance in hepatocellular carcinoma. Cancer Res 74, 1301-1306.
32. Resta R, Hooker SW, Hansen KR, Laurent AB, Park JL, Blackburn MR, Knudsen TB, Thompson LF (1993). Murine ecto-5'-nucleotidase (CD73): cDNA cloning and tissue distribution. Gene 133, 171-177.
33. Resta R, Yamashita Y, Thompson LF (1998). Ecto-enzyme and signaling functions of lymphocyte CD73. Immunol Rev 161, 95-109.
34. Roberts V, Lu B, Rajakumar S, Cowan PJ, Dwyer KM (2013). The CD39-adenosinergic axis in the pathogenesis of renal ischemia-reperfusion injury. Purinergic Signal 9, 135-143.
35. Singh RK, Cooper TA (2012). Pre-mRNA splicing in disease and therapeutics. Trends Mol Med 18, 472-482.
36. Sitkovsky MV, Hatfield S, Abbott R, Belikoff B, Lukashev D, Ohta A (2014). Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists. Cancer Immunol Res 2, 598-605.
37. Snider NT, Griggs NW, Singla A, Moons DS, Weerasinghe SV, Lok AS, Ruan C, Burant CF, Conjeevaram HS, Omary MB (2013). CD73 (ecto-5'-nucleotidase) hepatocyte levels differ across mouse strains and contribute to mallory-denk body formation. Hepatology 58, 1790-1800.
38. Snider NT, Weerasinghe SV, Singla A, Leonard JM, Hanada S, Andrews PC, Lok AS, Omary MB (2011). Energy determinants GAPDH and NDPK act as genetic modifiers for hepatocyte inclusion formation. J Cell Biol 195, 217-229.
39. Stagg J, Divisekera U, Duret H, Sparwasser T, Teng MW, Darcy PK, Smyth MJ (2011). CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res 71, 2892-2900.
40. Stagg J, Divisekera U, McLaughlin N, Sharkey J, Pommey S, Denoyer D, Dwyer KM, Smyth MJ (2010). Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci USA 107, 1547-1552.
41. St Hilaire C, Ziegler SG, Markello TC, Brusco A, Groden C, Gill F, Carlson-Donohoe H, Lederman RJ, Chen MY, Yang D, et al. (2011). NT5E muta?tions and arterial calcifications. N Engl J Med 364, 432-442.
42. Tamura K, Kanno T, Fujita Y, Gotoh A, Nakano T, Nishizaki T (2012). A(2a) adenosine receptor mediates HepG2 cell apoptosis by downregulating Bcl-X(L) expression and upregulating Bid expression. J Cell Biochem 113, 1766-1775.
43. Terp MG, Olesen KA, Arnspang EC, Lund RR, Lagerholm BC, Ditzel HJ, Leth-Larsen R (2013). Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells. J Immunol 191, 4165-4173.
44. Toth I, Le AQ, Hartjen P, Thomssen A, Matzat V, Lehmann C, Scheurich C, Beisel C, Busch P, Degen O, et al. (2013). Decreased frequency of CD73+CD8+ T cells of HIV-infected patients correlates with immune activation and T cell exhaustion. J Leukocyte Biol 94, 551-561.
45. Vembar SS, Brodsky JL (2008). One step at a time: endoplasmic reticulum-associated degradation. Nat Rev Mol Cell Biol 9, 944-957.
46. Wang L, Fan J, Thompson LF, Zhang Y, Shin T, Curiel TJ, Zhang B (2011). CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J Clin Invest 121, 2371-2382.
47. Wang H, Lee S, Nigro CL, Lattanzio L, Merlano M, Monteverde M, Matin R, Purdie K, Mladkova N, Bergamaschi D, et al. (2012). NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity. Br J Cancer 106, 1446-1452.
48. Zhang B (2010). CD73: a novel target for cancer immunotherapy. Cancer Res 70, 6407-6411.
49. Zimmermann H, Zebisch M, Strater N (2012). Cellular function and molecular structure of ecto-nucleotidases. Purinergic Signal 8, 437-502.
50. Zylka MJ (2011). Pain-relieving prospects for adenosine receptors and ectonucleotidases. Trends Mol Med 17, 188-196.